עמוד 1 מ 84 תוצאות
REFERENCE TO A SEQUENCE LISTING
This application includes a Sequence Listing submitted electronically as a text file named VDR+PARP_ST25.txt, created on Oct. 9, 2015, with a size of 3000 bytes. The Sequence Listing is incorporated by reference herein.
FIELD OF THE INVENTION
The invention relates
REFERENCE TO A SEQUENCE LISTING
This application includes a Sequence Listing submitted electronically as a text file named VDR+PARP_ST25.txt, created on Oct. 9, 2015, with a size of 3000 bytes. The Sequence Listing is incorporated by reference herein.
FIELD OF THE INVENTION
The invention relates
1. Field of the Invention
This invention relates to a method of detecting a predisposition for cancer using restriction fragment length polymorphism with a human poly (ADP-ribose) polymerase hybridization probe.
2. Brief Description of the Background Art
Carcinogenesis is a multistep process
FIELD OF THE INVENTION
This invention relates to methods of detecting a predisposition for cancer. The methods are based on the identification of restriction fragment length polymorphism within the DNA sequences for the pseudogene for human poly (ADP-ribose) polymerase using a hybridization probe
BACKGROUND OF THE INVENTION
Cancer is a term used to describe a wide variety of diseases that are each characterized by the uncontrolled growth of a particular type of cell. It begins in a tissue containing such a cell and, if the cancer has not spread to any additional tissues at the time of
CROSS-REFERENCE TO RELATED APPLICATIONS
This Non-provisional application claims priority under 35 U.S.C. .sctn.119(a) on Patent Application No(s). 100112343 filed in Taiwan, Republic of China Apr. 8, 2011, the entire contents of which are hereby incorporated by reference.
FIELD OF INVENTION
The
FIELD OF THE INVENTION
The invention relates generally to the field of formulation chemistry. More particularly, the invention relates to compounds, compositions, and methods for specifically inhibiting poly(ADP)-ribose polymerase 1 (PARP1) and for treating PARP1-associated diseases including, for
FIELD OF THE INVENTION
The invention relates generally to the field of in vitro screening assays. More particularly, the invention relates to a cell-free assay, which takes advantage of the histone H4-dependent activation of poly(ADP)-ribose polymerase 1 (PARP-1) whereby compounds or compositions
FIELD OF THE INVENTION
This invention relates to inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them.
BACKGROUND OF THE INVENTION
Poly(ADP-ribose)polymerase (PARP) is essential for facilitating DNA repair, controlling RNA transcription, mediating
BACKGROUND OF THE INVENTION
Cancer is a serious threat to modern society. Malignant cancerous growths, due to their unique characteristics, pose significant challenges for modern medicine. Their characteristics include uncontrollable cell proliferation resulting in unregulated growth of malignant
BACKGROUND OF THE INVENTION
The present invention relates to compositions and methods depending on a combination of therapeutic agents for the treatment of cancer, specifically the combination of a G-quadruplex-interactive compound that binds to G-quadruplexes in rDNA to release the nucleolin
STATEMENT REGARDING SEQUENCE LISTING
The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is 15-1330 Seq Listing_ST25.txt.
TECHNICAL FIELD
The present invention relates generally to methods of treatment for tuberous sclerosis complex (TSC), lymphangioleiomyomatosis (LAM), and/or other cancers.
BACKGROUND
Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease that predominantly affects women of childbearing
BACKGROUND
Defective DNA damage repair pathways and gene mutations in transcriptional pathways have been established as predominant targets for poly (ADP-ribose) polymerase (PARP) inhibition therapy in a wide spectrum of cancers (1-4). PARP-1, a nuclear enzyme, plays a crucial role in the DNA repair
BACKGROUND
Technical Field This disclosure relates to the field of chemotherapy treatment of patients having neoplastic disease. In particular, this disclosure relates to chemotherapy employing halogenated analogs of thymidine (abbreviated "HAT").
Background Information
A. Pain
Cancer-related pain,